Related Experiment Video
Updated: Aug 31, 2025

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast
Sebastian Gallo-Bernal1,2, Nasly Patino-Jaramillo3, Camilo A Calixto2,4
1Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.
Insights
Gadolinium contrast agents are vital for cardiac MRI but carry a risk of nephrogenic systemic fibrosis (NSF) in kidney disease patients. Newer agents are safer, yet awareness of NSF risks and prevention remains crucial.
Area of Science:
- Cardiology
- Radiology
- Nephrology
Background:
- Gadolinium-enhanced cardiac MRI is essential for cardiovascular disease diagnosis and management.
- Nephrogenic systemic fibrosis (NSF) is a serious concern in patients with renal dysfunction exposed to gadolinium contrast agents.
- While newer macrocyclic agents show improved safety profiles in chronic kidney disease, vigilance is necessary.
Purpose of the Study:
- To review the current evidence on the pathophysiology, clinical presentation, diagnosis, and prevention of NSF.
- To highlight the importance of understanding NSF risk factors and maintaining clinical suspicion.
- To provide guidance on the safe use of gadolinium-based contrast agents in at-risk populations.
Main Methods:
- Comprehensive literature review of studies on gadolinium-based contrast agents and NSF.
- Analysis of existing data on NSF physiopathology, clinical manifestations, and diagnostic criteria.
- Evaluation of prevention strategies and risk mitigation for NSF.
Main Results:
- Gadolinium exposure, particularly with older linear agents, is linked to NSF in patients with impaired renal function.
- Macrocyclic gadolinium agents demonstrate a significantly lower risk of NSF compared to linear agents.
- Early recognition and prevention strategies are key to managing NSF risk.
Conclusions:
- Despite advancements in gadolinium-based contrast agents, a thorough understanding of NSF is critical for safe clinical practice.
- Clinicians must remain vigilant for NSF in patients with cardiovascular conditions and renal impairment.
- Risk stratification and appropriate agent selection are paramount to minimize NSF incidence.
Abstract:
Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Nephrons

